KEI Briefing Note 2018:1. Bayh-Dole Obligations to Disclose Federal Funding Government oversight of under-reporting U.S. federal rights in patents. 1994. June 15, 1994, Inspector General Report to HHS on the under-reporting of federal funding of inventions at the Scripps Research… Continue Reading
KEI page on Research and Development Cost Transparency Legislation EB142: KEI statement on Addressing the global shortage of, and access to, medicines and vaccines, January 24th, 2018 Expert Panel charts a road map for WHO’s engagement on transparency and R&D,… Continue Reading
new: we have added a database of more than 1,000 federal court cases that cite 28 USC 1498 here: http://drugdatabase.info/28usc1498/ The United States government can use any patented invention, copyright, or protection of plant variety, original design or semiconductor design,… Continue Reading
India 2010 2010: India’s intervention to the WTO TRIPS Council: TRIPS plus enforcement trends, 2010-06-10 2011 2011: Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countries, 2011-05-28 2011: WTO TRIPS… Continue Reading
Brazil 1990-2000 Comments for the Working Group On Intellectual Property Rights, Third Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May 13-16,1997, 1997-05-16 2005 U.S. DoS Cable: U.S. PHARMA FIRMS THREATENED WITH LICENSING (Brazil), June 3, 2005. U.S. DoS… Continue Reading
On February 9, 2018, the Trump Administration released a paper by the Counsel of Economic Advisers (CEA) on drug pricing. The paper on pricing was thought to have been led by economist Tomas Philipson, appointed to the CEA by President… Continue Reading
KEI publishes research and commentary in a variety of journals, periodicals, books and other independent publishing platforms. In-house, KEI presents information in blogs, correspondence and reports, as well as in occasional KEI research notes and papers. Timelines (several) Timelines regarding… Continue Reading
Contacting James Love Work phone: +1.202.332.2670 | Mobile Phone +1.202.361.3040 | Email: james.love@keionline.org Twitter: @jamie_love Blue Sky: @jamielove@bsky.social (Give my office a call or give me another nudge if you have difficulty getting a response. I am overwhelmed at times… Continue Reading
On September 10, 2015, the National Association of Manufacturers (NAM), wrote to USTR expressing alarm at the European Union support of an indefinite extension of a WTO waiver of obligations to grant patents on pharmaceuticals for UN defined least developed countries (LDCs). In 2015, there were 954 million persons living in LDCs, with a per capita income of $964, according to the World Bank. The EU had aligned itself with health advocates trying to protect the bottom billion access to life saving medicines.
20 July 2016
For Immediate Release
Contacts
Knowledge Ecology International: Zack Struver, zack.struver@keionline.org, +1 (202) 332-2670
Public Citizen: Peter Maybarduk, pmaybarduk@citizen.org, +1 (202) 588-7755
Evidence shows pattern of interference in national and international efforts to improve access to affordable medicines, according to Doctors Without Borders (MSF USA), Knowledge Ecology International, Public Citizen, Oxfam, and other leading public interest groups.
Washington, DC — More than 50 public interest organizations and experts asked Secretary of State John Kerry today to explain evidence that the State Department recently pressured the United Nations and the governments of Colombia and India against taking action to improve access to affordable medicines, citing U.S. business interests and implying that relations with Washington would suffer.
Continue Reading